• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Nabriva Therapeutics plc

    11/19/21 12:57:43 PM ET
    $NBRV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NBRV alert in real time by email
    SC 13G 1 tm2133532d1_sc13g.htm SC 13G

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G 

    Under the Securities Exchange Act of 1934
    (Amendment No. __)* 

     

    NABRIVA THERAPEUTICS PLC
    (Name of Issuer)
     
    ORDINARY SHARES, $0.01 NOMINAL VALUE
    (Title of Class of Securities)
     
    G63637113
    (CUSIP Number)
     
    November 12, 2021

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ¨ Rule 13d-1(b)
      x Rule 13d-1(c)
      ¨ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    (Page 1 of 13 Pages)

     

     

     

     

     

      

    SCHEDULE 13G

     

    CUSIP NO. G63637113 Page 2 of 13
    1

    NAMES OF REPORTING PERSONS

    Lincoln Park Capital Fund, LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Illinois

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH:

    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    4,512,589

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    4,512,589

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    4,512,589

    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    7.96%

    12

    TYPE OF REPORTING PERSON

    OO

         
           

     

     

    SCHEDULE 13G

     

    CUSIP NO. G63637113 Page 3 of 13
    1

    NAMES OF REPORTING PERSONS

    Lincoln Park Capital, LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Illinois

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH:

    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    4,512,589

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    4,512,589

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    4,512,589

    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    7.96%

    12

    TYPE OF REPORTING PERSON

    OO

         
           

     

     

    SCHEDULE 13G

     

    CUSIP NO. G63637113 Page 4 of 13
    1

    NAMES OF REPORTING PERSONS

    Rockledge Capital Corporation

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Texas

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH:

    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    4,512,589

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    4,512,589

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    4,512,589

    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    7.96%

    12

    TYPE OF REPORTING PERSON

    CO

         
           

     

     

    SCHEDULE 13G

     

    CUSIP NO. G63637113 Page 5 of 13
    1

    NAMES OF REPORTING PERSONS

    Joshua B. Scheinfeld

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH:

    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    4,512,589

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    4,512,589

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    4,512,589

    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    7.96%

    12

    TYPE OF REPORTING PERSON

    IN

         
           

     

     

    SCHEDULE 13G

     

    CUSIP NO. G63637113 Page 6 of 13
    1

    NAMES OF REPORTING PERSONS

    Alex Noah Investors, Inc.

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Illinois

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH:

    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    4,512,589

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    4,512,589

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    4,512,589

    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    7.96%

    12

    TYPE OF REPORTING PERSON

    CO

         
           

     

     

    SCHEDULE 13G

     

    CUSIP NO. G63637113 Page 7 of 13
    1

    NAMES OF REPORTING PERSONS

    Jonathan I. Cope

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH:

    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    4,512,589

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    4,512,589

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    4,512,589

    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    7.96%

    12

    TYPE OF REPORTING PERSON

    IN

         
           

     

     

    SCHEDULE 13G

     

    CUSIP NO. G63637113  Page 8 of 13

      

    Item 1.

      

      (a)

    Name of Issuer:

     

       

    Nabriva Therapeutics plc, an Irish public limited company (“Issuer”) 

         
      (b)

    Address of Issuer’s Principal Executive Offices:

     

        25-28 North Wall Quay IFSC, Dublin 1, Ireland

      

    Item 2.

      

      (a)

    Name of Person Filing:

     

        Lincoln Park Capital Fund, LLC (“LPC Fund”)
        Lincoln Park Capital, LLC (“LPC”)
        Rockledge Capital Corporation (“RCC”)
        Joshua B. Scheinfeld (“Mr. Scheinfeld”)
        Alex Noah Investors, Inc. (“Alex Noah”)
       

    Jonathan I. Cope (“Mr. Cope” and, collectively with LPC Fund, LPC, RCC, Mr. Scheinfeld and Alex Noah, the “Reporting Persons”) 

         
      (b)

    Address of Principal Business Office, or if None, Residence:

     

        The address of the principal business office of each of the Reporting Persons is:
        440 North Wells, Suite 410
       

    Chicago, Illinois 60654

     

      (c)

    Citizenship:

     

        LPC Fund is an Illinois limited liability company
        LPC is an Illinois limited liability company
        RCC is a Texas corporation
        Mr. Scheinfeld is a United States citizen

     

     

     

     

     

     

    SCHEDULE 13G

     

    CUSIP NO. G63637113 Page 9 of 13

      

        Alex Noah is an Illinois corporation
       

    Mr. Cope is a United States citizen 

         
      (d)

    Title of Class of Securities: 

         
       

    Ordinary shares, $0.01 nominal value (“Ordinary Shares”) 

         
      (e)

    CUSIP Number: 

         
       

    G63637113 

     

    Item 3.

     

    If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

     

      (a) o Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
      (b) o Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
      (c) o Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
      (d) o Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
      (e) o An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
      (f) o An employee benefit plan or endowment fund in accordance with §240. 13d-1(b)(1)(ii)(F);
      (g) o A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
      (h) o A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
      (i) o A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
      (j) o A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
      (k) o Group, in accordance with §240.13d-1(b)(1)(ii)(K). 
           
      If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution ______________________

       

     

     

    SCHEDULE 13G

     

    CUSIP NO. G63637113 

    Page 10 of 13

      

    Item 4. Ownership. 

     

    Reporting person 

    Amount

    beneficially

    owned1:

      

    Percent

    of class2:

      

    Sole power

    to vote or

    direct

    the vote:

      

    Shared

    power to

    vote or to

    direct

    the vote3:

      

    Sole power to

    dispose or to

    direct the

    disposition of:

      

    Shared power

    to dispose or to

    direct the

    disposition of3:

     
    Lincoln Park Capital Fund, LLC   4,512,589    7.96%   0    4,512,589    0    4,512,589 
    Lincoln Park Capital, LLC   4,512,589    7.96%   0    4,512,589    0    4,512,589 
    Rockledge Capital Corporation   4,512,589    7.96%   0    4,512,589    0    4,512,589 
    Joshua B. Scheinfeld   4,512,589    7.96%   0    4,512,589    0    4,512,589 
    Alex Noah Investors, Inc.   4,512,589    7.96%   0    4,512,589    0    4,512,589 
    Jonathan I. Cope   4,512,589    7.96%   0    4,512,589    0    4,512,589 

      

    1Represents (i) 2,112,589 Ordinary Shares owned by LPC Fund prior to November 12, 2021 and (ii) 2,400,000 Ordinary Shares purchased by LPC Fund directly from the Issuer in private placement transactions completed between November 12, 2021 and November 18, 2021.

     

    2Based on the information contained in the Issuer’s Quarterly Report on 10-Q for the quarter ended September 30, 2021, filed with the Securities and Exchange Commission on November 9, 2021, there was a total of 54,316,604 Ordinary Shares outstanding as of October 31 2021, which number of outstanding shares excludes the 2,400,000 Ordinary Shares that were purchased by LPC Fund from the Issuer in private placement transactions after such date. The percentage is calculated as of November 18, 2021, and includes the 2,400,000 Ordinary Shares described in the sentence above, which are currently outstanding.

     

    3Represents the total number of Ordinary Shares beneficially owned by the Reporting Persons as of the date of this statement (as calculated pursuant to Section 13(d) of the Act and Rule 13d-3 promulgated thereunder), as described in Footnote 1 above.

      

     

     

     

    SCHEDULE 13G

     

    CUSIP NO. G63637113 

    Page 11 of 13

     

    As of November 18, 2021, LPC Fund beneficially owned, directly, the following securities of the Issuer: (i) 2,112,589 Ordinary Shares owned by LPC Fund prior to November 12, 2021 and (ii) 2,400,000 Ordinary Shares purchased by LPC Fund directly from the Issuer in the private placements between November 12, 2021 and November 18, 2021.

     

    LPC is the Managing Member of LPC Fund. RCC and Alex Noah are the Managing Members of LPC. Mr. Scheinfeld is the president and sole shareholder of RCC, as well as a principal of LPC. Mr. Cope is the president and sole shareholder of Alex Noah, as well as a principal of LPC. As a result of the foregoing, Mr. Scheinfeld and Mr. Cope have shared voting and shared investment power over the Ordinary Shares of the Issuer held directly by LPC Fund.

     

    Pursuant to Section 13(d) of the Act and the rules thereunder, each of LPC, RCC, Mr. Scheinfeld, Alex Noah, and Mr. Cope may be deemed to be a beneficial owner of the Ordinary Shares of the Issuer beneficially owned directly by LPC Fund.

     

    The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of any Ordinary Shares owned by another Reporting Person. Pursuant to Rule 13d-4 of the Act, each of LPC, RCC, Mr. Scheinfeld, Alex Noah, and Mr. Cope disclaims beneficial ownership of the Ordinary Shares of the Issuer held directly by LPC Fund.

     

     

     

    SCHEDULE 13G

     

    CUSIP NO. G63637113  Page 12 of 13

     

    Item 5.

    Ownership of Five Percent or Less of a Class. 

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨.

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person. 
       
      Not applicable. 
       
    Item 7. Identification and Classification of Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. 
       
      Not applicable. 
       
    Item 8. Identification and Classification of Members of the Group. 
       
      Not applicable. 
       
    Item 9. Notice of Dissolution of Group. 
       
      Not applicable. 
       
    Item 10. Certifications. 

      

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

    SCHEDULE 13G

     

    CUSIP NO. G63637113 Page 13 of 13

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 19, 2021

     

    LINCOLN PARK CAPITAL FUND, LLC   LINCOLN PARK CAPITAL, LLC
         
    BY: LINCOLN PARK CAPITAL, LLC   BY: ROCKLEDGE CAPITAL CORPORATION
         
    BY: ROCKLEDGE CAPITAL CORPORATION    
           
         
    By: /s/ Joshua B. Scheinfeld   By: /s/ Joshua B. Scheinfeld
      Name: Joshua B. Scheinfeld     Name: Joshua B. Scheinfeld
      Title: President     Title: President
         
    LINCOLN PARK CAPITAL FUND, LLC   LINCOLN PARK CAPITAL, LLC
         
    BY: LINCOLN PARK CAPITAL, LLC   BY: ALEX NOAH INVESTORS, INC.
         
    BY: ALEX NOAH INVESTORS, INC.    
           
         
    By: /s/ Jonathan I. Cope   By: /s/ Jonathan I. Cope
      Name: Jonathan I. Cope     Name: Jonathan I. Cope
      Title: President     Title: President
         
    ROCKLEDGE CAPITAL CORPORATION   ALEX NOAH INVESTORS, INC.
         
         
    By: /s/ Joshua B. Scheinfeld   By: /s/ Jonathan I. Cope
      Name: Joshua B. Scheinfeld     Name: Jonathan I. Cope
      Title: President     Title: President
         
    JOSHUA B. SCHEINFELD   JONATHAN I. COPE
         
         
    By: /s/ Joshua B. Scheinfeld   By: /s/ Jonathan I. Cope
      Name: Joshua B. Scheinfeld     Name: Jonathan I. Cope
      Title: President     Title: President

     

     

     

     

     

     

    LIST OF EXHIBITS

     

    Exhibit No. Description
       
    1 Joint Filing Agreement

     

     

     

     

     

     

    Get the next $NBRV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NBRV

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NBRV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Northland Securities reiterated coverage on Nabriva Therapeutics with a new price target

      Northland Securities reiterated coverage of Nabriva Therapeutics with a rating of Outperform and set a new price target of $6.00 from $9.00 previously

      3/12/21 8:13:45 AM ET
      $NBRV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NBRV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Hogan H Michael Iii

      3 - Nabriva Therapeutics plc (0001641640) (Issuer)

      7/10/23 5:51:57 PM ET
      $NBRV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Maggio David

      3 - Nabriva Therapeutics plc (0001641640) (Issuer)

      7/10/23 5:49:12 PM ET
      $NBRV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Gelone Steven P. covered exercise/tax liability with 140 units of Ordinary Shares, decreasing direct ownership by 0.97% to 14,283 units to cover taxes

      4 - Nabriva Therapeutics plc (0001641640) (Issuer)

      1/31/23 8:56:21 PM ET
      $NBRV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NBRV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Arbutus Appoints Two New Executives

      Karen Sims, MD, PhD Promoted to Chief Medical Officer Christopher Naftzger Appointed as General Counsel and Chief Compliance Officer WARMINSTER, Pa., July 10, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced the appointment of Dr. Karen Sims as Chief Medical Officer and Mr. Christopher Naftzger as General Counsel and Chief Compliance Officer. Mr. Naftzger succeeds Dr. Elizabeth Howard who will continue in an advisory role with respect to the on-going patent infringement l

      7/10/23 4:01:00 PM ET
      $ABUS
      $BMY
      $KRYS
      $NBRV
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Nabriva Therapeutics Provides Corporate Update

      -Company To Focus on Preserving Cash to Fund Orderly Wind Down of Operations- -Company To Continue Work With Torreya Capital On Asset Monetization- DUBLIN, Ireland, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV) today announced that, after an assessment of strategic options, its Board of Directors approved a plan to preserve cash in order to adequately fund an orderly wind down of the Company's operations. As previously disclosed, the Company engaged Torreya Capital to facilitate the exploration of a range of strategic options, including potential in-licensing or out-licensing of commercial stage assets. While the Company continues to work with Torreya Capital

      1/6/23 7:01:00 AM ET
      $NBRV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nabriva Therapeutics Announces Positive Topline Results from Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis

      - PK Data and Safety Profile Consistent with Previous Studies in Healthy Subjects – - Results Support Potential Utility of Lefamulin in Patients with Cystic Fibrosis - DUBLIN, Ireland and FORT WASHINGTON, Pa., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced positive topline results from their Phase 1 clinical trial that assessed the safety and pharmacokinetics (PK) of oral and intravenous (IV) XENLETA® (lefamulin) in adult patients with cystic fibrosis (CF). "We are excited to share positive topline

      11/28/22 7:01:00 AM ET
      $NBRV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NBRV
    SEC Filings

    See more
    • SEC Form 15-12G filed by Nabriva Therapeutics plc

      15-12G - Nabriva Therapeutics plc (0001641640) (Filer)

      10/25/23 1:43:51 PM ET
      $NBRV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Nabriva Therapeutics plc

      EFFECT - Nabriva Therapeutics plc (0001641640) (Filer)

      10/25/23 12:15:52 AM ET
      $NBRV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Nabriva Therapeutics plc

      S-8 POS - Nabriva Therapeutics plc (0001641640) (Filer)

      10/19/23 8:23:47 PM ET
      $NBRV
      Biotechnology: Pharmaceutical Preparations
      Health Care